NervGen Pharma : Click here to view Spinal Cord Injury Backgrounder presentation.

Enabling the Nervous System to Heal Itself

Our Spinal Cord Injury Phase 2a Clinical Trial Program January 11, 2022

Financial Disclosure Statement

Not an offer or solicitation: This document is provided for general information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security in any jurisdiction. The contents of this document have not been approved or disapproved by any securities commission or regulatory authority in Canada, the US or any other jurisdiction. It is neither sufficient for, nor intended to be used in connection with, any decision relating to the purchase or sale of any existing or future securities. Investors considering the purchase or sale of any securities should consult with independent professional advisors.

Forward-looking statements: Certain statements in this document about the Company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, including, without limitation, statements regarding advancement of NVG-291 in clinical development, the timing of human trials and regulatory approval, the potential efficacy of the Company's products and technology, and the potential to identify, evaluate and develop other drug candidates. The words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements are based on estimates and assumptions made by the Company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate and reasonable in the circumstances. Many factors could cause the Company's actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward- looking statements, including those described in the "Risk Factors" section of the Company's Annual Information Form, Prospectus Supplement, financial statements and Management Discussion and Analysis which can be found on SEDAR.com. All clinical development plans are subject to additional funding. Readers should not place undue reliance on forward-looking statements made in this document. Furthermore, unless otherwise stated, the forward-looking statements contained in this document are made as of the date of this document, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this document are expressly qualified by this cautionary statement.

2

NervGen Introduction

NervGen (OTCQX: NGENF, TSX: NGEN.V) is developing a revolutionary new class of "neuroreparative" drugs that enable the nervous system to broadly repair itself

Our mechanism of action enables multiple natural modes of repair, including plasticity, regeneration and remyelination

Published preclinical studies in numerous models: chronic and acute spinal cord injury, peripheral nerve injury, multiple sclerosis, stroke, optic neuritis, cardiac ischemia

Published preclinical results from animal models are unprecedented in scope, pattern and magnitude of demonstrated functional improvement, including motor function, sensory function, autonomic function and cognition

Strong and growing IP portfolio includes multiple patents issued and exclusive worldwide rights from Case Western Reserve University to the technology for all indications

NervGen's lead product, NVG-291,is the only drug of its kind in clinical development

• Phase 1 study in healthy volunteers is underway - Single Ascending Dose portion completed successfully
• Phase 1b/2 studies in spinal cord injury, Alzheimer's disease and multiple sclerosis planned for 2022

Since there are currently no approved drugs for nervous system repair, our platform technology has the potential to redefine the treatment paradigm for nervous system damage

3

Dramatic and Unprecedented Results

Placebo Administered	NVG-291 Administered
(back legs & tail dragging)	(back legs & tail active)

Video of spinal cord injury animal study after 7 weeks of treatment with placebo (control) or NVG-291

Rink et al., 2018*

4

NervGen was Founded on an Intense Interest in Spinal Cord Injury

Professor and researcher at CWRU in Cleveland, Ohio

Adjunct Professor at Cleveland

Clinic

Globally recognized researcher in spinal cord injury with multiple awards (Ameritec Prize, Christopher Reeve-Joan Irvine Research Medal)

Jerry Silver, PhD

Practicing dentist in Vancouver,

Canada

Co-founder of NervGen, serial investor and entrepreneur

Harold Punnett, DMD

Motivated to identify treatments for spinal cord injury due to tragic accident of family member that resulted in paraplegia, Dr. Punnett recognized the potential of Dr. Silver's groundbreaking

discoveries and created NervGen to commercialize the product of decades of his work

5